- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Incyte Corp Ltd
+ Add to WatchlistINCY:US
23.0400 USD 0.1300 0.56%As of 20:10:00 ET on 05/17/2013.
Snapshot for Incyte Corp Ltd (INCY)
| Open: | 23.2600 | Day's Range: | 22.7400 - 23.4300 | Volume: | 809,187 |
|---|---|---|---|---|---|
| Previous Close: | 23.1700 | 52wk Range: | 15.4300 - 26.2980 | 1-Yr Rtn: | +5.93% |
Key Statistics for INCY
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.1200 |
| Est. EPS (USD) (12/2013) | -0.0260 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 3,127.66 |
| Shares Outstanding (M) | 135.75 |
| 30 Day Average Volume | 935,452 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 9.1232 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for INCY
Company Profile & Key Executives for INCY
Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. The Company has drug discovery programs underway focused on the identification of new small molecule drugs for cancer and inflammation.
| Richard U De Schutter "Dick"Chairman | Paul A FriedmanPresident/CEO |
| David C HastingsExec VP/CFO | James M Daly "Jim"Exec VP/Chief Commercial Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
INCY News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page